• Citigroup maintains a "Buy" rating for Zenas BioPharma, Inc. (NASDAQ: ZBIO), indicating confidence in the company's future performance.
• Zenas BioPharma granted non-qualified stock options for 300,000 shares to new employees, aiming to align interests and retain talent.
• ZBIO's stock price has increased by 3.08%, with significant volatility observed in its daily trading range.

Zenas BioPharma, Inc. (NASDAQ: ZBIO) is a clinical-stage global biopharmaceutical company. It focuses on developing innovative therapies for patients with unmet medical needs. On December 22, 2025, Citigroup maintained its "Buy" rating for ZBIO, suggesting confidence in the company's future performance. At the time, ZBIO's stock was priced at $36.15.

Recently, Zenas BioPharma granted non-qualified stock options to two new employees. These options cover 300,000 shares of the company's common stock. The exercise price is set at $32.59 per share, matching the closing price on December 15, 2025. This move aligns with Nasdaq Listing Rule 5635(c)(4) and serves as an incentive for the new hires.

The stock options have a ten-year term and will vest over four years. After one year, 25% of the shares will vest. This strategy aims to retain talent and align employee interests with company performance. As of now, ZBIO's stock price has increased by 3.08%, reaching $36.15, reflecting positive market sentiment.

ZBIO's stock has shown significant volatility, with a daily range between $35.25 and $37.97. Over the past year, the stock has fluctuated from a low of $5.83 to a high of $41.50. The company's market capitalization stands at approximately $1.51 billion, with a trading volume of 1,401,267 shares, indicating active investor interest.